Custirsen sodium: Clusterin-targeting antisense therapy oncolytic

Drugs of the Future

Volumn 34, Issue 7, 2009, Pages 525-530

  Chi, K N ^a   Cleave, M E ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; BUSERELIN ACETATE; CARBOPLATIN; CHAPERONE; CISPLATIN; CLUSTERIN; CUSTIRSEN SODIUM; DOCETAXEL; FLUTAMIDE; GEMCITABINE; HEAT SHOCK PROTEIN; MESSENGER RNA; MITOXANTRONE; OGX 011; PACLITAXEL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTISENSE THERAPY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; KIDNEY CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; RIGOR; SIDE EFFECT; SWEATING; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84930540510     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.07.1386430     Document Type: Review

References (39)

1. Kasibhatla, S., Tseng, B. Why target apoptosis in cancer treatment? Mol Cancer Ther 2003, 2(6): 573-80.
2. Dai, C., Whitesell, L., Rogers, A.B., Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007,130(6): 1005-18.
3. Jones, S.E., Jomary, C. Clusterin. Int J Biochem Cell Biol 2002, 34(5): 427-31.
4. Humphreys, D.T., Carver, J.A., Easterbrook-Smith, S.B., Wilson, M.R. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999, 274(11): 6875-81.
5. Ammar, H., Closset, J.L. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2008, 283(19): 12851-61.
6. Wong, P., Borst, D.E., Farber, D. et al. Increased TRPM-2/clusterin mRNA levels during the time of retinal degeneration in mouse models of retinitis pigmentosa. Biochem Cell Biol 1994, 72(9-10): 439-46.
7. French, L.E., Sappino, A.P., Tschopp, J., Schifferli, J.A. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 1992, 90(5): 1919-25.
8. French, L.E., Wohlwend, A., Sappino, A.P., Tschopp, J., Schifferli, J.A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest 1994, 93(2): 877-84.
9. Zhang, Q., Zhou, W., Kundu, S. et al. The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro. BJU Int 2006, 98(2): 452-60.
10. Leskov, K.S., Klokov, D.Y., Li, J., Kinsella, T.J., Boothman, D.A. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003, 278(13): 11590-600.
11. Redondo, M., Villar, E., Torres-Munoz, J., Tellez, T., Morell, M., Petito, CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000,157(2): 393-9.
12. Miyake, H., Gleave, M., Kamidono, S., Hara, I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002, 59(1): 150-4.
13. July, L.V., Beraldi, E., So, A. et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004, 3(3): 223-32.
14. Miyake, H., Hara, S., Arakawa, S., Kamidono, S., Hara, I. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol 2002, 167(2, Pt. 1): 703-6.
15. Chen, X., Halberg, R.B., Ehrhardt, W.M., Torrealba, J., Dove, W.F. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA 2003, 100(16): 9530-5.
16. Steinberg, J., Oyasu, R., Lang, S. et al. Intracellular levels of SCP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997, 3(10): 1707-11.
17. Miyake, H., Nelson, C., Rennie, P.S., Gleave, M.E. Testosterone- repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000, 60(1): 170-6.
18. Sensibar, J.A., Sutkowski, D.M., Raffo, A. et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995, 55(11): 2431-7.
19. Zellweger, T., Chi, K., Miyake, H. et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002, 8(10): 3276-84.
20. Miyake, H., Chi, K.N., Gleave, M.E. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000, 6(5): 1655-63.
21. Michel, D., Chatelain, G., North, S., Brun, G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997, 328(Pt. 1): 45-50.
22. Zhang, H., Kim, J.K., Edwards, C.A., Xu, Z., Taichman, R., Wang, C.Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005, 7(9): 909-15.
23. Bubendorf, L., Kolmer, M., Kononen, J. et al. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999, 91(20): 1758-64.
24. Kyprianou, N., English, H.F., Isaacs, J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990, 50(12): 3748-53.
25. Crooke, S.T. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992, 32: 329-76.
26. Saijo, Y., Perlaky, L., Wang, H., Busch, H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 1994, 6(6): 243-9.
27. Zellweger, T., Miyake, H., Cooper, S. et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-0-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001, 298(3): 934-40.
28. Henry, S., Stecker, K., Brooks, D., Monteith, D., Conklin, B., Bennett, C.F. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 2000, 292(2): 468-79.
29. Cao, C., Shinohara, E.T., Li, H. et al. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 2005, 63(4): 1228-36.
30. Gleave, M., Jansen, B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann NY Acad Sci 2003, 1002: 95-104.
31. OncoGenex Technologies, Inc. Investigational Product: OGX-011 v5.0 (Investigator's Brochure). 2006.
32. Chi, K.N., Eisenhauer, E., Fazli, L. et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005, 97(17): 1287-96.
33. Chi, K.N., Siu, L.L., Hirte, H. et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008, 14(3): 833-9.
34. Laskin, J., Hao, D., Canil, C. et al. A phase I/II study of OGX-011 and a gemcitabine (GEM)/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 7596.
35. Chi, K.N., Hotte, S.J., Yu, E. et al. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 5069.
36. Chia, S., Dent, S., Ellard, S. et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009, 15(2): 708-13.
37. Saad, F., Hotte, S.J., North, S.A. et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 5002.
38. Chi, K.N., Hotte, S.J., Yu, E. et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009,27(15, Suppl.): Abst 5012.
39. Michels, J., Montemurro, T., Murray, N., Kollmannsberger, C., Chi, K.N. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 2006,106(5): 1041-6.